

Molecular basis of depression disorder and influence of omega-3 fatty acid on clinical symptoms and biomarkers

Submission date 10/10/2016	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 19/10/2016	Overall study status Completed	☐ Protocol
Last Edited 10/02/2026	Condition category Mental and Behavioural Disorders	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Background and study aims

Mood disorders in children and adolescents are a serious problem worldwide and are becoming more common in younger children. In recent years, research has been focused on the adjuvant therapy of depression (extra treatment to enhance the effects of the main treatment) to reduce the consumption of antidepressants, prolong remission (disease-free periods) and improve the outlook for these patients. The use of Omega-3 fatty acids as an adjuvant therapy is promising, with beneficial effects in the prevention and treatment of depression. This study aims to assess the effectiveness of omega-3 fatty acids-rich fish oil in the treatment of depression symptoms in children and adolescents treated for depression as well as to find out what effects this has on the body by looking at biochemical markers (substances).

Who can participate?

Children and adolescents aged 10 -18 years suffering from depression who are registered at the Department of Child Psychiatry of Comenius University and Child University Hospital in Bratislava.

What does the study involve?

Patients are randomly allocated to one of two groups. Those in the first group take 20 mL of omega-3 fish oil emulsion every day for 12 weeks in addition to their usual treatment, followed by 4 weeks of not taking the oil. Those in the second group take 20 mL of omega-6 sunflower oil emulsion every day for 12 weeks in addition to their usual treatment, followed by 4 weeks of not taking the oil. At the start of the study, every two weeks during the 12-week treatment period, and then at 16 weeks, participants have their symptoms of depression assessed and have blood and saliva samples taken to measure for chemical indicators of the effects the supplements are having on the body.

What are the possible benefits and risks of participating?

Participants who receive the omega-3 oil may benefit from a reduction of their depressive symptoms. There are no known risks involved with participating.

Where is the study run from?

1. Comenius University (Slovakia)
2. Comenius University and Child University Hospital (Slovakia)

Who is funding the study?

Slovak Research and Development Agency (Slovakia)

When is the study starting and how long is it expected to run for?

March 2013 to June 2020

Who is the main contact?

Professor Zdenka Durackova

zdenka.durackova@fmed.uniba.sk

Contact information

Type(s)

Scientific

Contact name

Prof Zdeňka Ďuračková

ORCID ID

<https://orcid.org/0000-0001-6956-7038>

Contact details

Institute of Medical Chemistry

Biochemistry and Clinical Biochemistry

Faculty of Medicine

Comenius University

Bratislava

Slovakia

813 72

+421 1 59357 564

zdenka.durackova@fmed.uniba.sk

Additional identifiers

Protocol serial number

APVV-15-0063

Study information

Scientific Title

Molecular bases of depressive disorders in children and adolescents, effect of omega-3 fatty acids, inflammation and oxidative stress

Acronym

Depoxin

Study objectives

Current study hypothesis as of 05/12/2023:

The current study aims to compare the efficacy of 12 weeks of administration of omega-3 fatty acids present in fish oil emulsion with a control oil emulsion (omega-6 fatty acids rich sunflower oil emulsion) alongside standard antidepressant treatment on depressive symptoms in children and adolescents (10 to 18 years old).

The study will investigate:

1. Clinical parameters: CDI score
2. Biochemical parameters: Lipid profile, fatty acid composition in serum LDL- and HDL-subfractions of lipoproteins, markers of oxidative stress and inflammation in blood, steroidal hormones in saliva, metabolites of kynurenine and serotonin pathway
3. Biophysical parameters: Fluidity of erythrocyte membranes
4. The length of telomeres in the buccal cells

Previous study hypothesis:

The aim of the current study is to compare the efficacy of 12 weeks administration of omega-3 fatty acids present in fish oil emulsion with a control oil emulsion (omega-6 fatty acids rich sunflower oil emulsion) alongside standard antidepressant treatment on depressive symptoms in children and adolescents (8 to 18 years old).

The study will investigate:

1. Clinical parameters: CDI score
2. Biochemical parameters: Lipid profile, fatty acid composition in serum LDL- and HDL-subfractions of lipoproteins, markers of oxidative stress and inflammation in blood, steroidal hormones in saliva
3. Biophysical parameters: Fluidity of erythrocyte membranes
4. The length of telomeres in the buccal cells

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 20/03/2013, Ethics Committee of the National Institute of Children's Diseases and the Faculty of Medicine, Comenius University Bratislava (Limbova 1, Bratislava, 833 40, Slovakia; +421 2 59371209, +421 2 59371927; detska.klinika@nudch.eu), ref: None available

Study design

Single-centre randomized double-blind comparator controlled interventional study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Depressive disorder (F32) or mixed anxiety and depressive disorder (F41.2)

Interventions

Patients are allocated in a 1:1 ratio to the two arms (Om3 and Om6) according to a computer-generated random sequence using block randomisation with a block-size of four. The randomisation was performed by the independent statistician. Patients are enrolled and assigned sequentially to adjuvant interventions by the physician. The allocation sequence is not available to any member of the research team until the databases had been completed and locked.

Intervention group: Participants receive 20ml of an omega-3 FA rich fish oil emulsion (Om3), which provides 2400 mg of total omega-3 FA; 1000 mg EPA and 750 mg DHA, EPA:DHA ratio = 1.33:1, for 12 weeks in addition to their standard antidepressant therapy, followed by a 4 week wash out period.

Control group: Participants receive an identically looking comparator omega-6 sunflower oil emulsion containing min 2467 mg of omega-6 linoleic acid provided by Cultech Ltd, Port Talbot (UK) for 12 weeks in addition to their standard antidepressant therapy, followed by a 4 week wash out period.

Clinical examinations take place at the beginning of the project (week 0), and every 2 weeks for 3 months (weeks 2, 4, 6, 8, 10, 12) and after following 4 week wash-out period, at week 16. Ratings are made using the self rated scale Children's Depression Inventory (CDI). Biological samples (blood, urine, saliva) are taken at the week 0, 6, 12 and 16.

Intervention Type

Supplement

Primary outcome(s)

Clinical symptoms of depression are determined using Children's Depression Inventory score (CDI) at baseline, 2, 4, 6, 8, 10, 12 and 16 weeks.

Key secondary outcome(s)

1. Basic biochemical marker levels (glucose, uric acid, lipid profile (total cholesterol, LDL-CH, HDL-CH, TAG), creatinine, CRP, liver enzymes ALT, AST) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16
2. Markers of oxidative stress (antioxidant enzymes SOD, GPx, CAT in Er, PON1 in serum, markers of lipid damage - lipoperoxides, 8-IsoP, protein damage - AOPP, serum protein carbonyls, nitrotyrosine, DNA damage in lymphocytes by comet assay, total antioxidant status-TEAC) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16
3. Markers of inflammation (CRP, calprotectin, cytokines and eicosanoids, thromboxanes) are measured by testing blood samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16
4. Hormones in saliva (cortisol, aldosterone) are measured by testing saliva samples taken at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16
5. Erythrocyte (Er) membrane fluidity is measured by spectrofluorimeter at baseline, at the week 6 and 12 of intervention and after wash-out period, at the week 16
6. Composition and content of serum fatty acids (FA) are measured by gas chromatography at baseline, at the week 6, 12 of intervention and after wash-out period, at the week 16
8. Length of DNA telomers in buccal cells is measured by qPCR at baseline and at 12 week intervention

Completion date

30/06/2020

Eligibility

Key inclusion criteria

1. Children and adolescents who met diagnostic criteria for depressive disorder or mixed anxiety and depressive disorder according to ICD 10
2. No signs of chronic somatic disease
3. Normal eating habits
4. Parents/guardians are willing to provide a signed informed consent
5. Children and adolescents are willing to provide blood, urine and saliva samples

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

10 years

Upper age limit

18 years

Sex

All

Total final enrolment

58

Key exclusion criteria

1. Chronic somatic diseases (endocrine, metabolic, autoimmune)
2. Dietary restrictions (vegetarians, lactose intolerance, celiac disease)
3. Psychotic disorders
4. Eating disorders
5. Addiction to psychoactive compounds
6. Personality disorders
7. Organic mental disorders
8. Pervasive developmental disorders

Date of first enrolment

01/03/2014

Date of final enrolment

30/06/2019

Locations

Countries of recruitment

Slovakia

Study participating centre

Comenius University

Department of Paediatric Psychiatry, Faculty of Medicine, The National Institute of Children's Diseases

Limbová 1

Bratislava

Slovakia

833 40

Study participating centre

Comenius University

Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry

Faculty of Medicine

Sasinkova 2

Bratislava

Slovakia

813 72

Sponsor information

Organisation

Comenius University

ROR

<https://ror.org/0587ef340>

Funder(s)

Funder type

Research organisation

Funder Name

Slovak Research and Development Agency (Agentúra na Podporu Výskumu a Vývoja)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from zdenka.durackova@fmed.uniba.sk and jana.trebaticka@fmed.uniba.sk

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Pilot study results	05/07/2017		Yes	No
Results article	Association of depression symptoms with levels of omega-3 and omega-6 fatty acids in serum	01/05/2020	18/03/2020	Yes	No
Results article	Lipid profile results	08/10/2020	22/10/2020	Yes	No
Results article	results for levels of thromboxane, brain-derived neurotrophic factor, homocysteine and vitamin D	27/03/2021	06/04/2021	Yes	No
Results article	Changes in stress hormones and markers of oxidative stress	10/08/2022	30/08/2022	Yes	No
Results article	The kynurenine and serotonin pathway, neopterin and biopterin in depressed children and adolescents: an impact of omega-3 fatty acids, and association with markers related to depressive disorder. A randomized, blinded, prospective study	13/02/2024	28/02/2024	Yes	No
Results article	Markers of oxidative stress	05/08/2021	10/02/2026	Yes	No